INONasdaqPharmaceutical PreparationsFiscal year ends December 31
INOVIO PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.00+0.01 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.35 (−57.45%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
INOVIO PHARMACEUTICALS, INC. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Free cash flow was -$80.78M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$79.26M
TTM Q2 2026
Free cash flow
-$80.78M
TTM Q2 2026
EPS, diluted
-$1.16
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $81.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 18.67
- Dividend yield
- –
- Free cash flow yield
- -98.97%
Fundamentals
- Revenue
- $0
- Net income
- -$67.43M
- EPS, diluted
- -$1.16
- Free cash flow
- -$80.78M
- Book value per share
- $0.05
- Diluted shares
- 82M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$0-100.0% YoY
Operating income
-$79.26M
Net income
-$67.43M
EPS, diluted
-$1.16
Free cash flow
-$80.78M
Reported periodTrailing twelve months